DiaSorin completed the acquisition of Luminex for $1.8bn.

DiaSorin, an Italian multinational biotechnology company, completed the acquisition of Luminex, a biotechnology company which develops, manufactures and markets proprietary biological testing technologies with applications in life-sciences, for $1.8bn. "With the merger into DiaSorin, we believe we can expand the value our customers receive through an expanded global product and service portfolio. The proposed transaction underscores the respected position Luminex has built in the marketplace and rewards our shareholders with attractive value for their shares," Nachum Shamir, Luminex Chairman, President and CEO.